Frontiers in Cardiovascular Medicine · Nov 19, 2026

Mendelian randomization in precision medicine for coronary heart disease: from causal discovery to clinical application

By Jinzhen Gong, Feng Wang, Banghua Liu et al.

Coronary heart disease (CHD) remains a leading cause of death worldwide, yet many treated patients continue to face high cardiovascular risk. Observational studies are limited by confounding and reverse causation, whereas randomized controlled trials are costly and time-consuming. Mendelian randomization (MR) uses inherited genetic variants as instrumental variables to investigate causal relationships before clinical trials are undertaken. This approach can inform precision medicine in CHD. This narrative review synthesizes published MR studies to outline a translational framework for CHD precision medicine. We first summarize evidence from MR studies that separate causal risk factors, including low-density lipoprotein cholesterol, lipoprotein(a), systolic blood pressure, and interleukin-6 signaling, from associated but noncausal biomarkers such as high-density lipoprotein cholesterol and C-reactive protein. We then review drug-target MR studies that prioritize therapeutic targets (PCSK9, ATP-citrate lyase, APOC3, ANGPTL3, and the interleukin-6 pathway), anticipate potential target-mediated effects, inform required exposure thresholds, and support trial design. We next consider polygenic risk scores as an adjacent precision-genetics tool for stratifying baseline risk, and distinguish prognostic enrichment from treatment-effect modification. Finally, we examine ancestry transferability, methodological credibility, and future directions including multi-omics and non-linear analyses. Evidence for each example is graded against an explicit five-level scheme. MR provides a preclinical filter that can prioritize causal pathways, nominate and de-risk drug targets, and inform trial design in CHD. Polygenic scores can stratify inherited baseline risk, but current evidence that they identify differential treatment response remains post hoc and inconsistent. Recent neutral outcomes trials targeting lipoprotein(a) and interleukin-6 show that genetic evidence can support decisions but is not clinical proof. Equitable implementation will require ancestrally diverse data, thorough sensitivity analyses, and prospective validation in randomized trials.

The paperJournal siteMechanisms

AgingResearch.News